As I stated many times before the key problem with this company is volume. It states it is building its US exposure with a BDM but it useless having that resource when you can produce volume for such a market. This is why Bondi Partners cannot get a deal. Elume are producing 30m/month and rising. HIV test yes have huge potential in 3rd World counties but they want only a cheap product. Atomo cannot make volume hence they get bits and pieces small orders that dont add up to much. John talks a big book but cannot deliver. The partners so far have been crap. Very disappointing management
AT1 Price at posting:
22.5¢ Sentiment: Hold Disclosure: Held
